MCID: SPN052
MIFTS: 56

Spondyloarthropathy

Categories: Bone diseases, Genetic diseases, Muscle diseases, Rare diseases

Aliases & Classifications for Spondyloarthropathy

MalaCards integrated aliases for Spondyloarthropathy:

Name: Spondyloarthropathy 12 15 40
Spondylarthropathies 44 73
Spondyloarthropathy, Susceptibility to 29
Spondarthropathy 12
Spondylarthrosis 12
Spondylarthritis 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1123
MeSH 44 D025242
SNOMED-CT 68 8847002

Summaries for Spondyloarthropathy

MalaCards based summary : Spondyloarthropathy, also known as spondylarthropathies, is related to spondyloarthropathy 1 and arthritis, and has symptoms including sciatica An important gene associated with Spondyloarthropathy is SPDA2 (Spondyloarthropathy, Susceptibility To, 2), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Adalimumab and Etanercept have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and heart, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Spondyloarthropathy or spondyloarthrosis refers to any joint disease of the vertebral column. As such,... more...

Related Diseases for Spondyloarthropathy

Diseases in the Spondyloarthropathy family:

Spondyloarthropathy 1 Spondyloarthropathy 2
Spondyloarthropathy 3 Juvenile Spondyloarthropathy

Diseases related to Spondyloarthropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 356)
# Related Disease Score Top Affiliating Genes
1 spondyloarthropathy 1 33.8 HLA-B IL17A MMP3 MRAP TNF
2 arthritis 30.8 IFNG IL10 IL17A IL6 MMP3 TNF
3 spondylitis 30.7 HLA-B HLA-C IL17A IL6 TNF
4 reactive arthritis 30.5 HLA-B IFNG IL10 IL17A TNF
5 anterior uveitis 30.4 HLA-A HLA-B IL6 TNF
6 uveitis 30.4 HLA-B IFNG IL10 IL17A IL4 TNF
7 rheumatoid arthritis 30.2 HLA-B IFNG IL10 IL17A IL4 IL6
8 connective tissue disease 30.1 IFNG IL10 IL6 TNF
9 colitis 30.1 IFNG IL10 IL17A IL4 IL6 TNF
10 ulcerative colitis 30.0 IFNG IL10 IL17A IL6 TNF
11 psoriatic arthritis 30.0 HLA-B HLA-C IL17A IL6 MMP3 TNF
12 mixed connective tissue disease 30.0 IFNG IL10 IL6 TNF
13 lyme disease 29.9 IL17A IL6 TNF
14 chlamydia 29.9 IFNG IL10 IL4 IL6 TNF
15 inflammatory bowel disease 29.9 HLA-B IFNG IL10 IL17A IL4 IL6
16 psoriasis 29.9 HLA-C IFNG IL10 IL17A IL4 IL6
17 myocarditis 29.9 HLA-B IL6 TNF
18 meningitis 29.8 IFNG IL10 IL6 TNF
19 synovitis 29.8 IL6 MMP3 TNF TNFSF11
20 conjunctivitis 29.8 IFNG IL4 IL6
21 acquired immunodeficiency syndrome 29.8 HLA-B IFNG IL10 IL6 TNF
22 osteoporosis 29.8 IFNG IL6 MMP3 TNF TNFSF11
23 human immunodeficiency virus infectious disease 29.7 IFNG IL10 IL6 TNF
24 demyelinating disease 29.7 IFNG IL10 IL17A TNF
25 osteomyelitis 29.5 IFNG IL10 IL6 TNF TNFSF11
26 viral infectious disease 29.5 IFNG IL10 IL4 IL6 TNF
27 herpes zoster 29.5 FCGR3A HLA-A HLA-B IFNG IL10
28 multiple sclerosis 29.4 IFNG IL10 IL17A IL4 IL6 TNF
29 systemic lupus erythematosus 29.2 FCGR3A IFNG IL10 IL17A IL4 IL6
30 autoimmune disease 29.0 FCGR3A HLA-B IFNG IL10 IL17A IL4
31 juvenile spondyloarthropathy 12.5
32 spondyloarthropathy 2 12.1
33 spondyloarthropathy 3 12.1
34 spondylarthropathy 11.5
35 ossification of the posterior longitudinal ligament of spine 11.1
36 enthesitis-related juvenile idiopathic arthritis 11.1
37 czech dysplasia 11.1
38 drug reaction with eosinophilia and systemic symptoms 10.4 HLA-B TNF
39 atrial tachyarrhythmia with short pr interval 10.3 HLA-A HLA-B
40 transient hypogammaglobulinemia 10.3 IL10 TNF
41 multifocal choroiditis 10.3 IL10 TNF
42 punctate inner choroidopathy 10.3 IL10 TNF
43 palladium allergic contact dermatitis 10.3 IL10 IL17A
44 postherpetic neuralgia 10.3 HLA-A HLA-B
45 neurosyphilis 10.3 IL10 IL17A
46 cephalosporin allergy 10.3 IFNG IL10
47 sporotrichosis 10.3 IFNG IL10
48 staphylococcal toxic shock syndrome 10.3 IFNG TNF
49 chronic beryllium disease 10.3 IFNG TNF
50 angioimmunoblastic lymphadenopathy with dysproteinemia 10.3 IL6 TNF

Graphical network of the top 20 diseases related to Spondyloarthropathy:



Diseases related to Spondyloarthropathy

Symptoms & Phenotypes for Spondyloarthropathy

UMLS symptoms related to Spondyloarthropathy:


sciatica

GenomeRNAi Phenotypes related to Spondyloarthropathy according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.14 HLA-A HLA-B HLA-C
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.14 HLA-A HLA-B HLA-C
3 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.14 HLA-A HLA-B HLA-C
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.14 HLA-C
5 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.14 HLA-C
6 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.14 HLA-A HLA-B HLA-C
7 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.14 HLA-C
8 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.14 HLA-A HLA-B HLA-C
9 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.14 HLA-A HLA-B HLA-C
10 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.14 HLA-C
11 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.14 HLA-A HLA-B HLA-C
12 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.14 HLA-C
13 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.14 HLA-A HLA-B HLA-C
14 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.14 HLA-A HLA-B HLA-C
15 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.14 HLA-C

MGI Mouse Phenotypes related to Spondyloarthropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 respiratory system MP:0005388 9.5 IFNG IL10 IL17A IL4 IL6 TNF
2 skeleton MP:0005390 9.23 IFNG IL10 IL17A IL4 IL6 MMP3

Drugs & Therapeutics for Spondyloarthropathy

Drugs for Spondyloarthropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 287)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adalimumab Approved Phase 4,Phase 2,Phase 3,Not Applicable 331731-18-1 16219006
2
Etanercept Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 185243-69-0
3
Sulfasalazine Approved Phase 4,Phase 2,Phase 3,Phase 1 599-79-1 5353980 5359476
4
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 169590-42-5 2662
5
Pamidronate Approved Phase 4 40391-99-9 4674
6
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1 428863-50-7
7
Infliximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 170277-31-3
8
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
9
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
10
Etoricoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 202409-33-4 123619
11
Indomethacin Approved, Investigational Phase 4,Phase 3 53-86-1 3715
12
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Not Applicable 15307-86-5 3033
13
Tramadol Approved, Investigational Phase 4,Not Applicable 27203-92-5 33741
14
Acetaminophen Approved Phase 4,Not Applicable,Early Phase 1 103-90-2 1983
15
Aceclofenac Approved, Investigational Phase 4 89796-99-6
16
Tofacitinib Approved, Investigational Phase 4,Phase 3,Phase 2 477600-75-2
17
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 73590-58-6 4594
18
Meloxicam Approved, Vet_approved Phase 4,Phase 3,Phase 2 71125-38-7 54677470 5281106
19
Hydroxychloroquine Approved Phase 4,Phase 3,Not Applicable 118-42-3 3652
20 Ixekizumab Approved, Investigational Phase 4,Phase 3 1143503-69-8
21
Apremilast Approved, Investigational Phase 4,Phase 3,Phase 2 608141-41-9 11561674
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
23 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Not Applicable
24 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Analgesics Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Not Applicable
29 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
30 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
31 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
32 Vaccines Phase 4,Phase 2,Not Applicable
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 beta-endorphin Phase 4
35 Melanocyte-Stimulating Hormones Phase 4
36 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
37 Adrenocorticotropic Hormone Phase 4
38 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Cyclooxygenase 2 Inhibitors Phase 4,Phase 3,Not Applicable
40 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Not Applicable
41 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
42 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Natriuretic Agents Phase 4
44 Natriuretic Peptide, Brain Phase 4
45 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 663)
# Name Status NCT ID Phase Drugs
1 Danish Multicenter Study of Adalimumab in Spondyloarthritis Unknown status NCT00477893 Phase 4 Adalimumab;Placebo
2 Treatment of Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Unknown status NCT02364479 Phase 4 etanercept;etanercept (half dose);placebo
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis Unknown status NCT01939132 Phase 4 Open label H.P. Acthar Gel
5 Dose Reduction of Etanercept in Patients With Ankylosing Spondylitis Unknown status NCT02638896 Phase 4 etanercept (Half-Dose);etanercept (Full-Dose);Sulfasalazine;Celecoxib
6 Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study Unknown status NCT02489760 Phase 4
7 Combined Treatment With TNF Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression Unknown status NCT02313727 Phase 4 Pamidronate
8 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
9 Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
10 Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Trial Completed NCT01718951 Phase 4 golimumab;Pamidronate
11 Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis Completed NCT03190603 Phase 4 Celecoxib
12 Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
13 A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis Completed NCT01298531 Phase 4 etanercept;etanercept;placebo
14 A Study of the Use of the Madrid Ultrasound Scoring System in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis Completed NCT02960035 Phase 4 etanercept;etanercept (half dose);placebo
15 A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment Completed NCT02897115 Phase 4
16 Serum Creatinine Change / Renal Adverse Effect With Use of Non-steroidal Painkillers in Axial Spondyloarthritis Patients Completed NCT03582332 Phase 4 Indomethacin SR, 75 Mg Oral Capsule, Extended Release;Indomethacin 25 Mg Oral Capsule;Etoricoxib 90 mg;Etoricoxib 60 mg
17 Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis Completed NCT01029847 Phase 4 Adalimumab;Placebo
18 Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy Completed NCT00420303 Phase 4 Etanercept
19 TNFalfa Blocking Treatment of Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
20 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
21 The NOR-SWITCH Study Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
22 Effects of Different Antirheumatic Treatments of Arthritis on Antibody Response Following Vaccination Using Prevenar® Completed NCT00828997 Phase 4
23 Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Completed NCT01934933 Phase 4 celebrex;Enbrel;Enbrel plus Celebrex
24 Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Following-up Study Completed NCT02915354 Phase 4 Etanercept
25 Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis Completed NCT00715091 Phase 4 diclophenac;diclophenac
26 Efficacy and Safety of Loxoprofen Hydrogel Patch in Patients With Ankylosing Spondylitis Completed NCT03800797 Phase 4 Loxoprofen sodium hydrogel patch;Loxoprofen sodium tablet
27 HUmira in Psoriatic Arthritis Completed NCT01465438 Phase 4 Adalimumab
28 Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis Completed NCT00245960 Phase 4 etanercept
29 A Study Of Celecoxib Versus Diclofenac In Patients With Ankylosing Spondylitis Completed NCT02528201 Phase 4 Celecoxib 200 milligrams;Celecoxib 400 milligrams;diclofenac 50 milligrams
30 Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis Completed NCT00432406 Phase 4 Infliximab;Etanercept
31 Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) Completed NCT01895764 Phase 4 Adalimumab;Methotrexate
32 The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) Completed NCT01668004 Phase 4
33 REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®) Completed NCT00127842 Phase 4 Etanercept
34 Total Glucosides Paeony Capsules in Maintaining Clinical Remission in Patients With Ankylosing Spondylitis Which Achieve Clinical Remission After Anti-TNF Therapy Completed NCT01517620 Phase 4 Total Glucosides Paeony Capsules
35 Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice Completed NCT01147874 Phase 4
36 Effect of Anti-TNF (Alpha) Treatment on Vascular Stiffness in Ankylosing Spondylitis (AS) Completed NCT01212653 Phase 4 Simponi
37 Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis Completed NCT00953979 Phase 4 kunxian capsule
38 Efficacy and Safety Study of Infliximab (Remicade) to Treat Early Ankylosing Spondylitis Completed NCT00936143 Phase 4 infliximab
39 Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain Completed NCT00873730 Phase 4 etanercept;etanercept/placebo
40 Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED) Completed NCT00779935 Phase 4
41 A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED) Completed NCT00779012 Phase 4
42 Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED) Completed NCT00778869 Phase 4
43 Tramadol/Acetaminophen(Ultracet) AS add-on Therapy in the Treatment of Patients With Ankylosing Spondylitis Completed NCT00647517 Phase 4 Ultracet
44 Infliximab and Methotrexate in Ankylosing Spondylitis Completed NCT00507403 Phase 4 infliximab
45 Study Evaluating Etanercept in Patients With Ankylosing Spondylitis Completed NCT00458185 Phase 4 etanercept
46 An Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis Completed NCT00444340 Phase 4 Enbrel (Etanercept)
47 Combination Methotrexate and Infliximab Completed NCT00432432 Phase 4 Infliximab and MTX
48 Centocor Microarray Study of Patients Completed NCT00462072 Phase 4 Infliximab
49 Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis Completed NCT00420238 Phase 4 Etanercept (Enbrel)
50 Extension Study Evaluating Etanercept in Ankylosing Spondylitis Completed NCT00410046 Phase 4 Enbrel (etanercept)

Search NIH Clinical Center for Spondyloarthropathy

Cochrane evidence based reviews: spondylarthropathies

Genetic Tests for Spondyloarthropathy

Genetic tests related to Spondyloarthropathy:

# Genetic test Affiliating Genes
1 Spondyloarthropathy, Susceptibility to 29

Anatomical Context for Spondyloarthropathy

MalaCards organs/tissues related to Spondyloarthropathy:

41
Bone, T Cells, Heart, Skin, Eye, Lung, Bone Marrow

Publications for Spondyloarthropathy

Articles related to Spondyloarthropathy:

(show top 50) (show all 636)
# Title Authors Year
1
Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn's disease-associated spondyloarthropathy. ( 29705819 )
2018
2
Management of Uveitis in Spondyloarthropathy: Current Trends. ( 29272246 )
2018
3
Pictorial Representation of Joint Involvement in Different Types of Spondyloarthropathy. ( 29342025 )
2018
4
Stability of fatigue, pain, patient global assessment and the Bath Ankylosing Spondylitis Functional Index (BASFI) in spondyloarthropathy patients with stable disease according to the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). ( 29299630 )
2018
5
Similar subclinical enthesitis in celiac and inflammatory bowel diseases by ultrasound suggests a gut enthesis axis independent of spondyloarthropathy spectrum. ( 29741671 )
2018
6
Quantifying the genetic risk for the development of axial spondyloarthropathy: could this become a diagnostic tool? ( 29702496 )
2018
7
Detection of Crohn Disease in Patients with Spondyloarthropathy: The SpACE Capsule Study. ( 29449505 )
2018
8
Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy. ( 30114486 )
2018
9
Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease. ( 30204909 )
2018
10
Identification of pathways significantly associated with spondyloarthropathy/ankylosing spondylitis using the sub‑pathway method. ( 30132545 )
2018
11
The Evolution of Central Retinal and Choroidal Thickness in Acute Anterior Uveitic Patients with Spondyloarthropathy. ( 30159168 )
2018
12
Spondyloarthropathy in vertebrae of the aquatic Cretaceous snake Lunaophis aquaticus, and its first recognition in modern snakes. ( 30291451 )
2018
13
Clinical outcomes after posterior cervical decompression and fusion surgery for destructive spondyloarthropathy in patients undergoing long-term hemodialysis: A matched case-control study. ( 30420294 )
2018
14
Comparison of patients with familial Mediterranean fever accompanied with sacroiliitis and patients with juvenile spondyloarthropathy. ( 28980897 )
2017
15
Back to Basics: Clinical versus Radiologic Recognition of Spondyloarthropathy. ( 28572477 )
2017
16
Cervical epidural injection in management of refractory pain and stiffness in spondyloarthropathy: A case report series. ( 28742241 )
2017
17
ACR Appropriateness Criteria(Ar) Chronic BackA PainA Suspected Sacroiliitis-Spondyloarthropathy. ( 28473095 )
2017
18
Seronegative Spondyloarthropathy ( 29083692 )
2017
19
An Unusual Cause of Myelopathy: Ochronotic Spondyloarthropathy with Positive HLA B27. ( 28240677 )
2017
20
Quadriplegia caused by an epidural abscess occurring at the same level of cervical destructive spondyloarthropathy: a case report. ( 28068970 )
2017
21
The Fascinating Paradox of Osteoporosis in Axial Spondyloarthropathy. ( 28966207 )
2017
22
Radiographic changes of cervical destructive spondyloarthropathy in long-term hemodialysis patients: A 9-year longitudinal observational study. ( 28373631 )
2017
23
Switching from Other Biologics to ZRC3197 (Adalimumab Biosimilar) in Patients with Spondyloarthropathy: A Prospective Evaluation from Real-Life Clinical Practice. ( 28836748 )
2017
24
Surgical Management for Destructive Atlantoaxial Spondyloarthropathy in Long-Term Hemodialysis Patients. ( 27771479 )
2017
25
Spondyloarthropathy: diagnostic imaging criteria for the detection of sacroiliitis. ( 28894334 )
2017
26
MRI assessment of sacroiliitis for the diagnosis of axial spondyloarthropathy: comparison of fat-saturated T2, STIR and contrast-enhanced sequences. ( 28749173 )
2017
27
Role of technetium-99m methylene diphosphonate SPECT/CT in the detection of sacroiliitis in patients with spondyloarthropathy - comparison with clinical markers and MRI. ( 28798229 )
2017
28
Co-treatment with golimumab and vedolizumab to treat severe UC and associated spondyloarthropathy. ( 29088342 )
2017
29
Dialysis-Related Spondyloarthropathy with Cervical Amyloidoma. ( 27491462 )
2016
30
Spondyloarthropathy-Like Findings and Diffuse Osteosclerosis as the Presenting Feature of Pseudohypoparathyroidism. ( 26906309 )
2016
31
The prevalence of spondyloarthropathy in fibromyalgia patients. ( 27919196 )
2016
32
Associations between functional FCGR2A R131H and FCGR3A F158V polymorphisms and responsiveness to TNF blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis. ( 27490376 )
2016
33
Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthropathy, Following Lyme Disease. ( 27636905 )
2016
34
Recombinant Salmonella typhimurium Outer membrane protein A is recognized by synovial fluid CD8 cells and stimulates synovial fluid mononuclear cells to produce IL17/IL23 in patients with Reactive arthritis and undifferentiated spondyloarthropathy. ( 27060348 )
2016
35
Improving recognition of spondyloarthropathy in primary care: an unmet need. ( 26823529 )
2016
36
High Prevalence of Back Pain and Axial Spondyloarthropathy in Patients with Hidradenitis Suppurativa. ( 27649417 )
2016
37
Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis. ( 27588089 )
2016
38
Challenges of cervical reconstruction for destructive spondyloarthropathy in renal osteodystrophy. ( 27052255 )
2016
39
Ultrasound-guided retro-calcaneal bursa corticosteroid injection for refractory Achilles tendinitis in patients with seronegative spondyloarthropathy: efficacy and follow-up study. ( 26894910 )
2016
40
Evaluation of treatments for sacroiliitis in spondyloarthropathy using the Spondyloarthritis Research Consortium Canada scoring system. ( 26832154 )
2016
41
Prognosis and adjacent segment disease after lumbar spinal fusion surgery for destructive spondyloarthropathy in long-term hemodialysis patients. ( 28027828 )
2016
42
Case 234: Neuropathic Spondyloarthropathy. ( 27643771 )
2016
43
Prevalence of axial spondyloarthropathy among patients suffering from Fibromyalgia - an MRI study with application of the ASAS classification criteria. ( 27390225 )
2016
44
Radiographic progression in patients with ankylosing spondylitis according to tumor necrosis factor blocker exposure: Observation Study of Korean Spondyloarthropathy Registry (OSKAR) data. ( 26948670 )
2016
45
Comparison on radiographic progression for 5 years between juvenile onset ankylosing spondylitis and adult onset ankylosing spondylitis: an observational study of the Korean SpondyloArthropathy Registry (OSKAR) data. ( 27051061 )
2016
46
Development of spondyloarthropathy following episodes of macrophage activation syndrome in children with heterozygous mutations in haemophagocytic lymphohistiocytosis-associated genes. ( 27383696 )
2016
47
Different Contributions of CDKAL1, KIF21B, and LRRK2/MUC19 Polymorphisms to SAPHO Syndrome, Rheumatoid Arthritis, Ankylosing Spondylitis, and Seronegative Spondyloarthropathy. ( 27936930 )
2016
48
Macular Changes Correlate with the Degree of Acute Anterior Uveitis in Patients with Spondyloarthropathy. ( 25140795 )
2016
49
Kinases inhibitors and small molecules: A new treatment tool for axial spondyloarthropathy? ( 27149917 )
2016
50
Spondyloarthropathy in inflammatory bowel disease patients on TNF inhibitors. ( 26337851 )
2015

Variations for Spondyloarthropathy

Expression for Spondyloarthropathy

Search GEO for disease gene expression data for Spondyloarthropathy.

Pathways for Spondyloarthropathy

Pathways related to Spondyloarthropathy according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 ALDOA FCGR3A HLA-A HLA-B HLA-C IFNG
2
Show member pathways
13.22 HLA-A HLA-B HLA-C IFNG IL10 IL17A
3
Show member pathways
13.02 HLA-A HLA-B HLA-C IL4 IL6 TNF
4
Show member pathways
12.8 HLA-A HLA-B HLA-C IFNG IL4 IL6
5
Show member pathways
12.8 HLA-A HLA-B HLA-C IFNG IL10 IL17A
6
Show member pathways
12.63 IFNG IL10 IL17A IL4 IL6 TNF
7
Show member pathways
12.61 IFNG IL10 IL17A IL6 TNF
8 12.6 IFNG IL10 IL17A IL4 TNF TNFSF11
9
Show member pathways
12.51 HLA-A HLA-B HLA-C IFNG
10
Show member pathways
12.5 FCGR3A HLA-A HLA-B HLA-C IFNG IL4
11 12.46 HLA-A HLA-B HLA-C IL6 TNF
12
Show member pathways
12.44 IFNG IL10 IL17A IL4 IL6 TNF
13
Show member pathways
12.39 IFNG IL10 IL4 IL6
14
Show member pathways
12.34 IFNG IL4 IL6 TNF
15 12.34 HLA-A HLA-B HLA-C IL6 TNF
16
Show member pathways
12.33 IFNG IL17A IL4 IL6 MMP3 TNF
17
Show member pathways
12.3 FCGR3A IFNG IL10 IL4 TNF
18 12.28 FCGR3A IFNG IL10 IL6 TNF
19
Show member pathways
12.21 IFNG IL4 IL6 TNF
20 12.2 ALDOA IL10 IL6 TNF
21 12.19 HLA-A HLA-B HLA-C IL6
22 12.16 FCGR3A HLA-A HLA-B HLA-C
23 12.11 FCGR3A HLA-A HLA-B HLA-C
24
Show member pathways
12.1 IFNG IL10 IL17A IL4 IL6
25
Show member pathways
12.09 IFNG IL10 IL17A IL6 TNF
26 12.08 FCGR3A IFNG TNF TNFSF11
27 12.04 IFNG IL4 IL6 TNF
28
Show member pathways
12.03 FCGR3A IFNG IL4 IL6 MMP3 TNF
29 12.01 IFNG IL10 IL4 IL6 TNF
30 11.97 IL10 IL17A IL4 IL6 MMP3 TNF
31 11.94 IL6 MMP3 TNF
32 11.93 IFNG IL10 IL6 TNF
33 11.89 ALDOA IFNG IL6
34 11.88 IL4 IL6 TNF
35
Show member pathways
11.82 HLA-A HLA-B HLA-C IFNG IL10 IL17A
36 11.81 IFNG IL10 IL6 TNF
37 11.8 IFNG IL4 IL6
38 11.8 IFNG IL10 IL17A IL4 TNF
39
Show member pathways
11.77 IFNG IL4 TNF
40 11.77 IL10 IL6 TNF
41 11.75 IFNG IL17A IL6 MMP3 TNF TNFSF11
42
Show member pathways
11.72 IFNG IL6 MMP3 TNF
43 11.68 IL4 IL6 TNF
44
Show member pathways
11.66 HLA-A IFNG TNF
45 11.59 IL10 IL4 IL6 TNF
46 11.58 IFNG IL6 TNF
47 11.58 IFNG IL10 IL6 TNF
48 11.54 IFNG IL6 TNF TNFSF11
49 11.53 IFNG IL10 IL4
50 11.39 IL10 IL6 TNF

GO Terms for Spondyloarthropathy

Cellular components related to Spondyloarthropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 ALDOA IFNG IL10 IL17A IL4 IL6
2 extracellular space GO:0005615 9.65 ALDOA IFNG IL10 IL17A IL4 IL6
3 recycling endosome membrane GO:0055038 9.58 HLA-A HLA-B HLA-C
4 phagocytic vesicle membrane GO:0030670 9.54 HLA-A HLA-B HLA-C
5 ER to Golgi transport vesicle membrane GO:0012507 9.43 HLA-A HLA-B HLA-C
6 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.33 HLA-A HLA-B HLA-C
7 MHC class I protein complex GO:0042612 8.8 HLA-A HLA-B HLA-C

Biological processes related to Spondyloarthropathy according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.98 IL10 IL17A IL6 NLRP2 TNF
2 regulation of immune response GO:0050776 9.83 FCGR3A HLA-A HLA-B HLA-C IL4
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.82 IFNG IL4 IL6
4 response to glucocorticoid GO:0051384 9.81 IL10 IL6 TNF
5 type I interferon signaling pathway GO:0060337 9.81 HLA-A HLA-B HLA-C
6 positive regulation of DNA-binding transcription factor activity GO:0051091 9.81 IL10 IL6 TNF TNFSF11
7 humoral immune response GO:0006959 9.8 IFNG IL6 TNF
8 regulation of signaling receptor activity GO:0010469 9.8 IFNG IL10 IL17A IL4 IL6 TNF
9 antigen processing and presentation GO:0019882 9.75 HLA-A HLA-B HLA-C
10 interferon-gamma-mediated signaling pathway GO:0060333 9.71 HLA-A HLA-B HLA-C IFNG
11 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.7 HLA-A HLA-B HLA-C
12 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.67 IFNG TNF
13 negative regulation of growth of symbiont in host GO:0044130 9.66 IL10 TNF
14 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.66 IL10 TNF
15 regulation of osteoclast differentiation GO:0045670 9.65 TNF TNFSF11
16 negative regulation of lipid storage GO:0010888 9.65 IL6 TNF
17 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.65 HLA-A HLA-B HLA-C
18 endothelial cell apoptotic process GO:0072577 9.64 IL10 TNF
19 positive regulation of MHC class II biosynthetic process GO:0045348 9.63 IL10 IL4
20 positive regulation of T cell mediated cytotoxicity GO:0001916 9.63 HLA-A HLA-B HLA-C
21 negative regulation of cytokine secretion involved in immune response GO:0002740 9.61 IL10 TNF
22 positive regulation of neuroinflammatory response GO:0150078 9.61 IL6 TNF
23 positive regulation of interleukin-23 production GO:0032747 9.6 IFNG IL17A
24 protection from natural killer cell mediated cytotoxicity GO:0042270 9.59 HLA-A HLA-B
25 regulation of isotype switching GO:0045191 9.57 IL10 IL4
26 type 2 immune response GO:0042092 9.56 IL10 IL4
27 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.55 IFNG TNF
28 receptor biosynthetic process GO:0032800 9.54 IL10 TNF
29 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.54 HLA-A HLA-B HLA-C
30 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.5 HLA-A HLA-B HLA-C
31 cytokine-mediated signaling pathway GO:0019221 9.5 IL10 IL17A IL4 IL6 MMP3 TNF
32 positive regulation of vitamin D biosynthetic process GO:0060557 9.49 IFNG TNF
33 positive regulation of osteoclast differentiation GO:0045672 9.46 IFNG IL17A TNF TNFSF11
34 immune response GO:0006955 9.36 FCGR3A HLA-A HLA-B HLA-C IFNG IL10
35 positive regulation of gene expression GO:0010628 10.02 IFNG IL4 IL6 TNF TNFSF11

Molecular functions related to Spondyloarthropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 IFNG IL10 IL17A IL4 IL6 TNF
2 peptide antigen binding GO:0042605 9.13 HLA-A HLA-B HLA-C

Sources for Spondyloarthropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....